Print Friendly, PDF & Email

5) If the government is serious about Make in India for APIs and boosting R&D spending by pharmaceutical companies, it must shun price controls as a policy measure. Discuss measures required to be taken by the government in augmenting the Pharma sector.(250 words)

Topic:  Indian Economy and issues relating to planning, mobilization of resources, growth, development and employment. Achievements of Indians in science & technology; indigenization of technology and developing new technology.

5) If the government is serious about Make in India for APIs and boosting R&D spending by pharmaceutical companies, it must shun price controls as a policy measure. Discuss measures required to be taken by the government in augmenting the Pharma sector.(250 words)

Financialexpress

Why this question:

The article captures that the government is mulling over excluding medicines made from locally manufactured active pharmaceutical ingredient (API)—the key raw material for the production of a drug—from price control. The move, according to a Mint report, is aimed at pushing manufacture of APIs in India to reduce import dependence.

Key demand of the question:

One has to discuss in depth the need to do away the price controlling policies by the government with respect to APIs in the pharma industry so as to boost the Make in India drive for the sector.

Directive:

DiscussThis is an all-encompassing directive – you have to debate on paper by going through the details of the issues concerned by examining each one of them. You have to give reasons for both for and against arguments.

Structure of the answer:

Introduction: 

In brief define what APIs are. 

Body:

Discuss the context of the question as to what steps the government is trying to take.

Explain in what way the price control was affecting domestic manufacture of pharma products.

Discuss the nuances of Draft Pharmaceuticals Policy 2017,

Justify that if the government is serious about Make in India for APIs and boosting R&D spending by pharmaceutical companies, it must shun price controls as a policy measure. To keep medicines affordable for the masses, it must subsidize through bulk purchases for its Jan Aushadhi and other outlets.

Conclusion:

Conclude  with way forward.